AstraZeneca has become the latest big pharma company to devote new cash to its US manufacturing muscle this year as it ...

AstraZeneca said on Monday its experimental weight-loss pill, licensed a year ago from China's Eccogene for up to $2 billion, ...

The European Commission (EC) has approved AstraZeneca’s Bydureon BCise, a new weekly formulation of established GLP-1 diabetes drug with the added benefit of glucose reduction, better weight ...

While Novo Nordisk and Lilly are the undisputed leaders in weight management right now, a number of pharmaceutical companies ...

AstraZeneca showcased positive early data on three experimental weight-loss drugs at ObesityWeek, highlighting its oral GLP-1 ...

AstraZeneca Plc said its experimental obesity pill was well-tolerated by patients with type-2 diabetes as it presented data from several studies testing its three new weight-loss medicines.

AstraZeneca raised its full-year guidance after third-quarter results topped analysts’ expectations, boosted by its cancer ...

The pharmaceutical giant expects overall sales and core earnings per share to rise by a high-teens percentage at constant ...

An estimated 828 million adults (420 women, 408 men) had diabetes in 2022, an increase of 630 million since 1990. India (212 ...

AstraZeneca PLC shed £15 billion in market capitalization on Tuesday, after investors were underwhelmed by early data from a ...